Aparicio, J., Manrique, A., Capdevila, J., Boza, F., Galvan, P., Richart, P., . . . Maurel, J. (2022). Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: The BEYOND study (GEMCAD 17-01).
Citación estilo ChicagoAparicio, J., et al. Randomized Phase II Trial of FOLFIRI-panitumumab Compared With FOLFIRI Alone in Patients With RAS Wild-type Circulating Tumor DNA Metastatic Colorectal Cancer Beyond Progression to First-line FOLFOX-panitumumab: The BEYOND Study (GEMCAD 17-01). 2022.
Cita MLAAparicio, J., et al. Randomized Phase II Trial of FOLFIRI-panitumumab Compared With FOLFIRI Alone in Patients With RAS Wild-type Circulating Tumor DNA Metastatic Colorectal Cancer Beyond Progression to First-line FOLFOX-panitumumab: The BEYOND Study (GEMCAD 17-01). 2022.